x
Blau Farmacêutica S.A.
Blau is a multinational leading company, a pioneer in developing Biotech medicines in Brazil, with more than 35 years of innovation and technology. Equipped with cutting-edge technology to produce Active Pharmaceutical Ingredients (APIs), with global operations (Americas, Europe and EUA) and export to more than 20 countries.
BLANVER FARMOQUIMICA E FARMACEUTICA S.A.
Blanver is a Brazilian pharmaceutical company with over 40 years of experience and global presence. We develop, license, and commercialize high-quality medicines and APIs for the Latin American market.
Biotimize
Biotimize is a Brazilian CDMO that provides personalized biotechnology and bioprocess engineering-based services for preclinical and clinical studies to global biopharmaceutical companies. Being the main driver of new regulatory models that value innovation, Biotimize works to develop new approaches to create a scenario where it is possible to democratize access to science and healing and create a positive impact on people. Our services (Mammalian cells, Bacteria, Yeast, Virus) – Cell Line Development – Process Development and Optimization – Bioproduction – Analytics Development – Technical- Economic Analysis – PoC material production – Preclinical material production – Clinical material production
Biotimize Biotechnology as a Service
Founded in 2016 in São Paulo – Brazil, Biotimize has the mission of transforming lives through biotechnology, enabling ideas, treatments, and dreams to become reality. Biotimize works to develop new approaches to create a scenario where it is possible to democratize access to science and healing and create a positive impact on people. Through the Biotechnology as a Service (BTaaS) model, we provide biotechnology and bioprocess engineering-based services to global companies or institutions. The solutions are of a personalized nature and can range from advisory support in projects developed by the client to the complete development of a product by our team. We are able to follow all the necessary steps to obtain biopharmaceuticals for pre-clinical studies. In doing so, we can speed up the arrival of new technologies (from both mammalian cells and microorganisms) to the market based on (under OECD GLP certification): • Cell line development (vector design; transient transfection; streamlined CLD process; final clones with expected quality and expression levels; RCB generation) • Process development and optimization (media and feed development; clone evaluation in shake flasks; PD in bioreactors 600 mL – 4L; harvest/clarification; chromatography – Protein A, AEX, CEX, IMAC, HIC, Mixed model; viral inactivation; formulation; sterile filtration; stability) • Analytical and QC testing (Title – ELISA, Protein A, Bradford, A280; PQ – CEX, SES; Purity – SDS-Page; endotoxin; HCP; HCD; ELISA) • Non-GMP production (production of up to 4L of transient expression or stable pools/clones for tox studies; low endotoxin purification) • Bioprocess technical-economic analysis
Biosima
BioSima, a biotech company founded in 2022 and based in Brazil, has pioneered an innovative platform for developing exosome-based biopharmaceuticals. BioSima’s products are focused on addressing unmet medical needs by conventional therapies applied in Endocrinology (Diabetes), bone reconstruction (Orthopedics and Dentistry), and Neurology (Alzheimer’s disease). BioSima’s biopharmaceuticals are developed utilizing cutting-edge R&D techniques applicable for regenerative medicine, employing exosome concentrates—nanometric extracellular vesicles produced naturally by living cells and concentrated through specific patented methods. Acting as active ingredients of biopharmaceuticals, these exosomes deliver their genetic and protein cargo to target local undifferentiated cells, aiming to stimulate their proliferative and differentiation potential for healing and repairing of diseased living tissues and organs. BioSima has built a solid track record in Brazil’s biotechnology innovation landscape, achieving significant financial milestones that strengthen its scientific and technological development capacity. Since its inception, the company has stood out in highly competitive public funding programs for applied research, securing support through federal initiatives in Brazil such as FINEP and the Ministry of Science, Technology and Innovation (MCTI). A key highlight is its approval under the “INOVADOC-Brazil” FINEP program, which provides non-reimbursable grants to high-impact projects in health and sustainability. In addition to government-backed funding, BioSima has successfully attracted seed capital from private sources — including angel investors with equity-based funding mechanisms tailored to deep tech startups. This financial support has enabled the company to structure a robust program for the development of exosome-based therapeutic products. It has also driven the consolidation of BioSima’s R&D infrastructure, the development of analytical methods, and the execution of preclinical safety and efficacy studies, both in vitro and in vivo. These advancements have positioned BioSima strategically to start regulatory planning and the technical processes required for clinical trial submissions to health authorities such as ANVISA (Brazil), FDA and EMA, in compliance with international good practices in biopharmaceutical development. The company’s financial and operational achievements to date reflect not only its strong technical foundation but also its institutional readiness and business maturity to meet the complex challenges of healthcare innovation.
BIONOVIS SA – COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACEUTICA
Bionovis is a Brazilian pharmaceutical biotechnology company whose objective is to promote the research & development, manufacturing, distribution, and commercialization of highly complex biopharmaceuticals. We constantly invest in highly qualified human resources and in the acquisition of equipment and technology. This structure allows us to fully produce several innovative biological, biosimilar and biopharmaceutical medicines for the treatment of various pathologies, increasing access to high-technology medicines for patients. In more than a decade of operation, we have built partnerships with major global leaders in the biopharmaceutical sector. Through these partnerships, we receive the complete technology to produce innovative biopharmaceuticals and biosimilars. In our history, we have already positively impacted around 1 million patients, through the provision of more than 16 million vials and syringes of biopharmaceuticals. We are committed to ensuring Brazil’s self-sufficiency in the development and manufacturing of high-quality, highly complex biological products, increasingly expanding the access of Brazilians to these medicines. Aligned with global standards and requirements required of the National Health Surveillance Agency – ANVISA (approved in November 2023 – API and December 2024 – Fill and Finish), regulatory agencies in the United States (Food and Drug Administration – FDA – expected for 2027) and Europe (European Medicines Agency – EMA – expected for 2027). Bionovis is looking for opportunities to license biological and biosimilar products for the Brazilian market and offers C(D)MO capabilities for Brazil and Latin America.
Biominas Brasil
We are specialists in creating and developing the best connections and businesses in bio. We connect researchers and entrepreneurs to companies and investors, and vice versa. We create services, programs, and environments that, in a proven way, contribute to the construction of successful businesses based on the interaction between the main players in the areas of life sciences and biotechnology.
Biolab Sanus Farmaceutica
Biolab Pharma at a Glance: (1) Biolab is a 100% Brazilian pharmaceutical company focused on prescription products. (2). The company is ranked as the #3 largest sales force in the Brazilian Market, with 1,600 sales reps that visit over 320,000 doctors monthly. (3). We are among Brazil’s top 10 pharmaceutical companies in sales in just 25 years of history. (4). For FY2023 is expected annual gross revenue of ~500MM. Ranked #5 prescription pharma. (5). Leading pharmaceutical private company in Brazil in sales and prescription in the cardiology field. (6). We have an extensive and robust portfolio in dermatology, gastroenterology, pediatrics, and central nervous system segments. (7). The company has over 3,500 fully dedicated employees to work with innovation from the operation to the top management. (8). We have high development capacity, state-of-the-art facilities with 4 manufacture sites, 3 R&D centers in Brazil, continuously invests in developing innovative products. (9). Biolab counting on promising R&D in Canada with various “me better” products based on differentiated technology platforms. (10). Innovation is the DNA of the company. Biolab is looking for partners that expect the best-in-class go-to-market for innovative products. (11). Biolab seeks distribution rights for Brazil and for some selected LATAM markets by financing other life sciences companies in the late stage, aiming to have life-enhancing and affordable products for patients. (12). We are interested in strategic and exclusive prescription products based on Radical and Incremental innovation (me better) with proven clinical trials and late-stage drug discoveries (Phase III). (13). The company has over 50 international partnerships of products from in-licensing deals ongoing with global pharma companies, such as Eli Lilly, Amgen, Takeda, Novartis, Ferring, Faes Pharma, Menarini, Kowa, among others.